Trial Profile
Single-center, Open-label, Single-arm Exploratory Clinical Trial of Anlotinib Monotherapy and Combination Therapy in Relapsed / Refractory MM Previously Treated With Immunomodulator and Protease Inhibitor Regimens
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 Sep 2023
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 27 Sep 2022 New trial record